Heron Therapeutics, Inc. (HRTX): Cost of Revenue
$41.35M
Year ended 2025-12-31
$45.24M
Trailing 12 months to 2026-06-30
-9.0%
3-year compound annual growth
+2.7%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $41.35M | +7.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $38.65M | -40.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $65.11M | +18.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $54.87M | +19.2% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $46.02M | +27.2% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $36.19M | -41.3% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $61.62M | +124.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $27.51M | +499.7% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $4.59M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $35.0K | n/a | 2019-02-22, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $41.35M | +7.0% |
| Liquidia Corp (LQDA) | 2024-12-31 | $5.88M | +103.6% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $0 | -100.0% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $73.85M | +68.0% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $22.60M | +183.4% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $93.12M | +6.9% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $40.97M | -8.7% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $151.75M | +0.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $88.57M | +2.5% |
Compare HRTX, LQDA, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗